Natera shares jump after Japan approval for Signatera companion diagnostic
Natera said Japan’s Pharmaceuticals and Medical Devices Agency granted regulatory approval for Signatera as a companion diagnostic in muscle-invasive bladder cancer; the stock rose 5.2% in the afternoon session.
2% in the afternoon session after the company said Japan's Pharmaceuticals and Medical Devices Agency granted regulatory approval for its Signatera test as a companion diagnostic in muscle-invasive bladder cancer.